Want to see CLGN full AI Analyst Report?
Top Page
Collplant Holdings
(NASDAQ:CLGN)
Select Model
Select Model
Rating:44Neutral
Price Target:
$3.50
▲(872.22% Upside)
Action:Reiterated
Date:10/01/26
The score is primarily held down by very weak financial performance (minimal/declining revenue, heavy losses, and sustained cash burn with equity erosion). Technicals are only neutral with the stock still well below its 200-day average, and valuation remains unattractive due to negative earnings and no dividend yield support.
Positive Factors
Proprietary rhCollagen platform
CollPlant’s plant-derived recombinant human collagen platform addresses several regenerative medicine and biofabrication applications, creating multiple potential commercialization paths. Its proprietary biomaterial foundation can support product sales, collaborations, licensing and royalties as medical and bioprinting adoption develops.
Negative Factors
Very small and declining revenue
Revenue remains extremely small and has declined, indicating that CollPlant’s core technologies have not yet produced a reliable commercial earnings base. Low and volatile sales reduce operating leverage, limit internal funding capacity and leave results highly dependent on future milestones or successful partner commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary rhCollagen platform
CollPlant’s plant-derived recombinant human collagen platform addresses several regenerative medicine and biofabrication applications, creating multiple potential commercialization paths. Its proprietary biomaterial foundation can support product sales, collaborations, licensing and royalties as medical and bioprinting adoption develops.
Read all positive factors
Collplant Holdings (CLGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.75M
Dividend YieldN/A
Average Volume (3M)742.18K
Price to Earnings (P/E)―
Beta (1Y)0.12
Revenue Growth-86.76%
EPS Growth16.63%
CountryUS
Employees39
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-9.39
Shares Outstanding1,890,821
10 Day Avg. Volume77,626
30 Day Avg. Volume742,181
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.81
Price to Sales (P/S)7.21
P/FCF Ratio-1.81
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.85
Revenue Forecast (FY)$2.00M
Collplant Holdings Business Overview & Revenue Model
Company Description
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe. The company primarily engages in the three-dimensional (3D) bioprinting of tissues and organs, alongside dev...
How the Company Makes Money
CollPlant makes money primarily by monetizing its plant-derived recombinant human collagen (rhCollagen) platform through (1) commercial sales/supply of rhCollagen and collagen-based biomaterials used as inputs for medical and biofabrication applic...
Collplant Holdings Earnings Call Summary
Earnings Call Date:Mar 26, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Dec 02, 2026
Earnings Call Sentiment Neutral
Despite significant advancements in preclinical programs and continued collaboration with AbbVie, the company experienced a sharp decline in annual revenue and increased net losses, presenting a mixed financial outlook.Positive Updates
Photocurable Dermal Filler Preclinical Success
The photocurable dermal filler candidate is in the preclinical phase, targeting a market valued at approximately $6.3 billion with a compound annual growth rate of 10%. Positive feedback from leaders in aesthetic medicine suggests it could be a game-changer for facial plastic surgery.
Negative Updates
Significant Revenue Decline
Revenue for the year ended December 31, 2024, was $515,000, a sharp decrease from $11 million in 2023, mainly due to a $10 million milestone payment in 2023 not repeated in 2024.
Read all updates
Q4-2024 Updates
Positive
Negative
Photocurable Dermal Filler Preclinical Success
The photocurable dermal filler candidate is in the preclinical phase, targeting a market valued at approximately $6.3 billion with a compound annual growth rate of 10%. Positive feedback from leaders in aesthetic medicine suggests it could be a game-changer for facial plastic surgery.
Read all positive updates
Company Guidance
During the CollPlant Biotechnologies Ltd. investor call, CEO Yehiel Tal and Deputy CEO Eran Rotem provided guidance centered on their regenerative medicine advancements, notably highlighting their proprietary photocurable dermal filler and regenerative breast implant programs. The dermal filler, aimed at a market valued at approximately $6.3 billion with a 10% CAGR, is currently in the preclinical phase, with plans to launch a clinical trial within two years. The regenerative breast implant program is progressing with preclinical testing of 250cc commercial-sized prototypes, showing promising results in tissue integration without complications. Financially, CollPlant reported a decrease in revenue from $11 million in 2023 to $515,000 in 2024, primarily due to a $10 million milestone payment from AbbVie in 2023. Despite a GAAP net loss of $16.6 million in 2024 compared to $7 million in 2023, the company maintains a stable cash position of $11.9 million as of December 31, 2024, not accounting for an additional $2 million payment from AbbVie, ensuring operational capability into the second quarter of 2026.Collplant Holdings Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 318.00K | 2.37M | 515.00K | 10.96M | 299.00K | 15.64M |
| Gross Profit | -1.66M | 624.00K | -2.15M | 7.87M | -1.18M | 13.64M |
| EBITDA | -11.52M | -10.56M | -15.55M | -5.91M | -15.81M | 1.05M |
| Net Income | -12.51M | -11.49M | -16.61M | -7.02M | -16.93M | 237.00K |
Balance Sheet | ||||||
| Total Assets | 7.20M | 10.79M | 18.71M | 34.13M | 37.77M | 51.22M |
| Cash, Cash Equivalents and Short-Term Investments | 2.95M | 5.95M | 11.91M | 26.67M | 29.65M | 43.30M |
| Total Debt | 2.66M | 2.85M | 3.08M | 3.16M | 2.91M | 3.61M |
| Total Liabilities | 4.25M | 4.70M | 5.25M | 5.79M | 5.49M | 6.10M |
| Stockholders Equity | 2.94M | 6.08M | 13.46M | 28.34M | 32.28M | 45.12M |
Cash Flow | ||||||
| Free Cash Flow | -11.70M | -9.45M | -14.58M | -3.72M | -14.97M | 1.07M |
| Operating Cash Flow | -11.61M | -9.42M | -14.09M | -2.76M | -13.70M | 2.50M |
| Investing Cash Flow | -8.88K | -27.00K | -539.00K | -1.16M | 28.92M | -31.56M |
| Financing Cash Flow | 2.45M | 3.10M | 9.00K | 1.11M | 1.87M | 38.76M |
Collplant Holdings Technical Analysis
Negative
0.36
Price Trends
3.43
Positive
3.57
Negative
6.21
Negative
Market Momentum
0.08
Positive
45.08
Neutral
9.50
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLGN, the sentiment is Negative. The current price of 0.36 is below the 20-day moving average (MA) of 3.79, below the 50-day MA of 3.43, and below the 200-day MA of 6.21, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 45.08 is Neutral, neither overbought nor oversold. The STOCH value of 9.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLGN.
Collplant Holdings Risk Analysis
Collplant Holdings disclosed 81 risk factors in its most recent earnings report. Collplant Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Collplant Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $109.07M | -3.51 | -311.07% | ― | ― | 61.30% | |
53 Neutral | $278.42M | 0.83 | -6.74% | ― | -100.00% | 95.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $13.52M | -0.36 | -218.59% | ― | ― | 38.14% | |
44 Neutral | $6.75M | -0.37 | -215.58% | ― | -86.76% | 16.63% | |
44 Neutral | $16.74M | -1.07 | -748.08% | ― | ― | ― | |
43 Neutral | $7.68M | -0.44 | 1070.23% | ― | ― | ― |
* Healthcare Sector Average
CLGN
Collplant Holdings
3.46
-20.54
-85.58%
DARE
Daré Bioscience
0.84
-1.34
-61.38%
PASG
Passage Bio
4.12
-3.83
-48.18%
PYPD
PolyPid
5.19
1.69
48.29%
SABS
SAB Biotherapeutics
2.98
0.92
44.66%
NRSN
Neurosense Therapeutics Ltd.
3.94
-21.07
-84.26%
Collplant Holdings Corporate Events
CollPlant Deepens Photonic Computing Push with LightSolver Deal as Q2 Loss Narrows
Sep 30, 2026
On September 30, 2026, CollPlant reported second-quarter 2026 results showing GAAP revenues of $108,000, down from $179,000 a year earlier, and a GAAP net loss of $2.7 million, reflecting lower rhCollagen product sales and the absence of a prior-y...
CollPlant’s LightSolver Reports Major Photonic Computing Breakthrough in HPC Study
Sep 24, 2026
On September 24, 2026, CollPlant subsidiary LightSolver and Germany’s High-Performance Computing Center Stuttgart published joint research showing that LightSolver’s pure photonic Laser Processing Unit architecture can dramatically spe...
CollPlant Regains Nasdaq Bid Price Compliance, Shoring Up Dual Tech Strategy
Sep 22, 2026
On September 22, 2026, CollPlant Biotechnologies Ltd., a deep-tech and biotech firm, disclosed that it had regained compliance with Nasdaq’s minimum bid price rule after shares closed at or above $1.00 for ten consecutive sessions earlier in...
CollPlant Highlights LightSolver Optical Computing Strategy in Updated September 2026 Presentation
Sep 18, 2026
On September 17, 2026, CollPlant Biotechnologies posted an updated corporate presentation highlighting its planned acquisition and commercialization of LightSolver, a developer of optical high-performance computing systems that use interacting las...
CollPlant Adds LightSolver Founder to Board After Closing Photonic Computing Acquisition
Sep 4, 2026
CollPlant Biotechnologies announced on September 4, 2026 that it has appointed Dr. Ruti Ben Shlomi, CEO and co-founder of LightSolver Ltd., to its Board of Directors following the closing of CollPlant’s acquisition of LightSolver. Her appoin...
CollPlant Closes LightSolver Acquisition, Expands Into Photonic Computing
Sep 3, 2026
On September 3, 2026, CollPlant Biotechnologies closed its acquisition of Israeli deep-tech firm LightSolver, marking its formal entry into the high-performance computing and photonics sectors. The deal, structured primarily in equity with an addi...
CollPlant Biotechnologies Implements 1-for-10 Reverse Share Split to Maintain Nasdaq Listing
Sep 1, 2026
CollPlant Biotechnologies announced that its board approved a one-for-ten reverse share split of its ordinary shares, following shareholder approval at an extraordinary general meeting on August 18, 2026. The reverse split will take effect when tr...
CollPlant to Acquire LightSolver, Pivoting Into Photonic Supercomputing
Aug 31, 2026
CollPlant Biotechnologies Ltd., based in Rehovot, Israel, operates at the intersection of regenerative medicine and advanced high‑performance computing. In healthcare, it develops recombinant human collagen-based products for 3D bioprinting ...
CollPlant Shareholders Approve All Proposals at August 18 Extraordinary Meeting
Aug 18, 2026
On August 18, 2026, CollPlant Biotechnologies Ltd. held an Extraordinary General Meeting of Shareholders in Israel as part of its ongoing corporate governance processes. The meeting followed a formal notice issued on July 28, 2026 to investors pur...
CollPlant Biotechnologies Bolsters Authorized Share Capital and Validates Resale Shares After July Private Placement
Aug 6, 2026
On August 6, 2026, CollPlant Biotechnologies filed a Form 6-K in the U.S. to report that its shareholders had previously approved, on July 29, 2026, a substantial increase in authorized share capital from 30 million to 500 million ordinary shares....
CollPlant Shareholders Approve Proposal at Extraordinary General Meeting
Jul 29, 2026
On July 29, 2026, CollPlant Biotechnologies held an Extraordinary General Meeting of Shareholders in Israel. At this meeting, shareholders approved the single proposal presented, which had been outlined earlier in the company’s July 7, 2026 ...
CollPlant Biotechnologies Calls August 18 Extraordinary Meeting to Approve Reverse Share Split and Capital Changes
Jul 28, 2026
On July 28, 2026, CollPlant Biotechnologies filed a Form 6-K in the United States announcing it will convene an extraordinary general meeting of shareholders in Tel Aviv on August 18, 2026, at 10:00 a.m. Israel time. The meeting will be held at th...
CollPlant Biotechnologies Calls July 29 Extraordinary Meeting to Approve Major Share Capital Increase
Jul 7, 2026
On July 7, 2026, CollPlant Biotechnologies announced it will convene an extraordinary general meeting of shareholders in Tel Aviv on July 29, 2026 to vote on a significant increase in its authorized share capital. The board is asking investors to ...
CollPlant Biotechnologies Raises $2.6 Million via Private Placement to Fund R&D and Strategic Deals
Jul 1, 2026
On June 29, 2026, CollPlant Biotechnologies entered a definitive securities purchase agreement for a $2.6 million private placement of 7,647,061 ordinary shares or equivalents, along with series A and series B warrants priced at $0.34 per unit, wi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.